Extracted from this filing and checked against the source text.
Restructurings & Charges
SEC 8-K Item 2.05/2.06
confidence 0.9
Elanco Animal Health Inc announced a restructuring with charges of approximately $175 million affecting global headcount reduction and closure of Kansas City, Missouri implant facility and exit from portion of Monheim, Germany facility (approximately 300 employees, plus an approximate 300 employees whose positions will be replaced).
- Type
- restructuring
- Charge
- approximately $175 million
- Affected area
- global headcount reduction and closure of Kansas City, Missouri implant facility and exit from portion of Monheim, Germany facility
- Headcount
- approximately 300 employees, plus an approximate 300 employees whose positions will be replaced
Exact text from the filing
On December 5, 2025, the Board of Directors of Elanco Animal Health Incorporated (the “Company”) authorized a restructuring plan with respect to its workforce (the “Restructuring Plan”) to support margin expansion, optimize the Company’s footprint, and further invest in innovation. The Restructuring Plan will result in a global headcount reduction of approximately 300 employees, plus an approximate 300 employees whose positions will be replaced with positions in growth areas or in lower-cost geographies. Expected pretax charges associated with the Restructuring Plan total approximately $175 million, the majority of which will be incurred in 2025, including an estimated $130 million of cash-based costs, most of which is expected to be paid in the next 2 years, and an estimated $45 million of non-cash asset impairment charges primarily related to the Company’s closure of its Kansas City, Missouri implant facility and exit from a portion of its Monheim, Germany facility.
View on SEC.gov